Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Bioprinting 2021

Marc Ferrer's Biography

Marc Ferrer, Director, 3D Tissue Model Laboratory, NIH/NCATS

Marc Ferrer is currently the director of the 3D tissue model laboratory at NCATS. He graduated with a BSc degree in Organic Chemistry from the University of Barcelona, Spain, in 1989, and received his Ph.D. degree in Biological Chemistry from the University of Minnesota, in 1994. He was a postdoctoral fellow at Harvard University from 1995-1999, where he used structure-based chemical approaches for the development of anti-HIV small molecules. He joined the Department of Automated Biotechnology at the Merck Research Laboratories in 1999, where he became Director of Assay Development and High Throughput Screening. In 2010, he joined the NIH Chemical Genomics Center where he worked with investigators in the academic community to implement high throughput screening and medicinal chemistry programs for the discovery of small molecule probes to study protein function in vitro and in animal models of diseases. In the last four years, he has led the implementation of a 3D Tissue Model Laboratory at NCATS, a multidisciplinary group that uses 3D tissue biofabrication techniques, including 3D Bioprinting, to create assay models of human live tissues in multi-well plate format for drug discovery. Dr. Ferrer has co-authored more than 120 peer-reviewed scientific publications.

Marc Ferrer Image

Bioengineered Tissue Models for Drug Discovery and Development

Friday, 19 March 2021 at 09:00

Add to Calendar ▼2021-03-19 09:00:002021-03-19 10:00:00Europe/LondonBioengineered Tissue Models for Drug Discovery and Development3D-Bioprinting 2021 in

Tissue equivalents produced using bioengineering technologies are emerging as robust and versatile cellular assay platforms for drug discovery and development.  Bioengineering technologies enable the production of spatially controlled tissues with tailored physiological complexity using iPSC-derived or primary cells, in multi-well plate platforms amenable for medium throughput screening.

Operationalization of the use of bioengineered 3D organotypic models with existing automation screening platforms meets with challenges in cell production, reproducible tissue biofabrication in multi-well plate format, 3D phenotypic assays, and data generation and processing challenges.  Examples of bioengineered tissue models and their use for drug screening will be discussed.

Add to Calendar ▼2021-03-18 00:00:002021-03-19 00:00:00Europe/London3D-Bioprinting 20213D-Bioprinting 2021 in